NGEN NervGen Pharma Corp

$NGEN The muted response to this news is absolutely bizzare. Some people here have ben calling management inept while they are quietly but aggressively executing on their primary objective. It usally takes a phase 3 registrational trial 6-9 months to go from FDA alignment to actively recruting - NGEN management did it in 5.7 months. It can also take MANY MONTHS on average, especially in a CNS trial, to go from "actively recruiting" to "first patient dosed" ... they just accomplished that in 2 weeks... that is almost UNHEARD OF, check for yourself. The most important thing is that management is able to execute ahead of schedule... so when they say they will complete recruitment in H2 2027 and topline readout in H1 2028... I think they're going to beat that. We could be roughly a year from topline readout for a drug that addresses a massive unmet need, has zero competition and potential peak sales in the billions... INSANE UNDERVALUATION.

$NGEN Is there any other company even remotely close to NervGen's NVG-291? Because I've looked and they're only at animal studies. That's a decade or more behind Nervgen. And that is only if they have some promise. NVG-291 is already being proven effective. In humans. That is a major leap from rat studies. As anyone who follows pharma knows that rats often respond to treatments much easier/better than humans. The data gathered on NVG-291 alone is worth billions. The data will allow these peptide treatments to leapfrog years in advancements.

$NGEN Got my average down to 2.19. I'll add 300 more shares tomorrow if it goes any lower. My goal is to have enough extra shares to sell to buy this peptide at the estimated 200k cost, when it gets FDA approval and I get it prescribed off label for my Progressive MS. After getting CAR-T cell therapy from the trial I'm joining, my spinal cord repair can happen without hindrance from constant attack by my immune system.

$NGEN If you want to talk value for money, please show me another Biotech that has started an FDA sanctioned and approved ph 3 design trial with multiple prestigious medical centers around North America! This design was built on the phenomenal results of their ph 2 trial, going after a largely unmet need/treatment in spinal cord injuries and potentially many other neuroreparative conditions. AND have a market cap of under $200 million???????? Exactly! I predict this little known tiny Biotech will make major waves in the next 12 to 18 months and will probably be bought out by some lucky BP!

$NGEN $IBRX Rough days ahead with the market sell off and shaky market sentiment, everyone’s skiddish right now it seems. Glad I’m a long term investor who’s in long term winners like these😎

$NGEN I have that Yabushi guy blocked now, but saw the comments in your reshare and it's too funny, have to comment. The chart below shows some of the STRONG data produced from our phase 2. Do like I did, ask a mathematical model what the probability is that all of this just occured 'by chance'... the number I got just from picking three of these data points randomly was a 6 in a million chance or 0.000006 p value, lol. In other words, we know the drug is biologically active. So the purpose of the phase 3 is to ensure we're doing enough to eliminate 'statistical noise'. Going from a 20 person trial to a 150 person trial massively reduces the risk of statistical noise. By the way, ask your AI buddy why the FDA agreed to a trial design with 150 patients rather than 300 or 600+ (as is typical in CNS)... it is because the data from phase 2 was compelling enough that a much small would be sufficient to create a very high (95-99%) chance of statistical success.

​The risk/reward setup for $NGEN is one of the most compelling in early-stage biotech. Lead drug NVG-291 targets the biological barrier preventing neural repair after spinal cord injuries, and Phase 1b/2a CONNECT SCI trial data proved it: showing an 825% increase in upper-body nervous system connectivity, ~3.7x greater hand function improvement, and 75% overall recovery vs 33% on placebo. ​Following a $60M offering, NervGen holds $61.1M in cash, a runway that fully funds operations through the Phase 3 RESTORE primary readout in 1H 2028 (enrollment wraps 2H 2027). Eliminating near-term dilution risk provides rare stability for a small-cap play. With zero approved neuroreparative drugs on the market, the upside is massive. High-conviction play with great science and the balance sheet to back it up!

$NGEN I keep adding. Never thought I would but this is a gift. Think of where they were when the raised $60M and now. Arguably we are in better shape at a cheaper price. We have officially starting dosing in p3. We have centers opening up. And yet our market cap, even fully diluted is paltry. And btw, those options would bring in nice cash too. All in all, silly cheap. I add and hold when this happens. And if you think p3 will fail, then yes, stay away. But think of all the data from p2. Hard not to be optimistic about p3. At least that’s my take, hence why I keep adding

$NGEN 🏥 NervGen Pharma Corp. announced the first participant was dosed in the Phase 3 registrational RESTORE study evaluating NVG-291 in chronic cervical motor-incomplete spinal cord injury to potentially improve hand function and quality of life.

$NGEN leerink R&D Day Supports Confidence in RESTORE Study ● Bottom line: NervGen’s R&D Day was constructive, and we came away incrementally more positive on the rationale and design of the Phase 3 RESTORE study in traumatic spinal cord injury (tSCI), specifically more confidence in the Phase 3 primary endpoint. Management provided additional scientific context supporting NVG-291’s mechanism of action, clarified why modest improvements in hand function can meaningfully improve patients’ lives, and gave more detail on the GRASSP Quantitative Prehension (QtP) measure, which is the primary endpoint of RESTORE. We believe RESTORE is well-designed to capture NVG-291’s potential benefit, with an FDA-aligned endpoint, the same chronic cervical motor-incomplete population studied in Phase 2a CONNECT, rigorous GRASSP standardization, and close monitoring of at-home dosing. We believe gain in hand function is important, and with over 300K patients with tSCI in the US alone, the unmet need is real.

$NGEN it's hilarious how everyone blames management for a stock that is in Phase 3 trials and will only move substantially when those results come out. Everybody always points fingers at the wrong things.

$NGEN finally added. I have a very big position that has melted in value. So even buying a bit here seems to make sense to average down. I do believe they will succeed in their p3. The drug works, it’s not a placebo effect. Even small n, the gait analysis was statistically significant. That’s for me a clear sign of the drug at work, in conjunction with all the other evidence.

$NGEN you have to be complete piece of shit to short this for nickel's and dimes when it could go up to 100$ a share in a year. How much of a tool do you have to be to wish the company that will help millions of people fails. Go back to scamming elderly people you broke bitch

$NGEN I have been buying but getting filled in tiny increments...my last fill was anywhere from 2 shares to up to 770 shares and lots of numbers in between. I can't say for sure that this is the bottom but it is close enough in my opinion to start buying again. It seems that the volume seems to be backing up my theory. I just can't believe these shares are this cheap with everything NGEN is bringing to the table! Look at analyst price targets! This baby is on sale!!!

$NGEN This price is obviously insane. Let me quickly explain why I'm so bullish. Our primary endpoint, quantitative prehension, already got statistical significance for the t test in phase 2, and with about 50 patients would have gotten it for the lme test as well. For the ArcEx device, a lot of PT alone after 2 months resulted in getting +1.3. For AXER-204 (I believe no physical therapy) the qtp test was somewhere around +0.9 after 3 months. Both drug and placebo had the same result. For us, phase 2 had placebo at +0.4 and the adjusted value was +1.0. For phase 3 we're not doing any extra physical therapy, and hand PT for phase 2 wasn't as much as for legs if I remember correctly. Clearly qtp in phase 3 shouldn't really go above +1.0. The questions are how much the drug will work, and what will the standard deviation be? I feel good about it, and if the SD will be on the lower end, like the adjusted phase 2 results, then we should be just fine. People need to calm down.

$NGEN I recall first hearing about this ticker on BioPub in 2021 I believe it was. I dabbled in it, but was in CAPR around the 100 mil MC mark heading into its P3. I decided many years later to see where this ticker was at, then saw the press releases and that it was trading heavily sub 200 mil MC… i thought very unique MoA for a potential high TAM… so slapped the ask and trying to get into LTCG status. I have certainly heard of worse setups. Good luck to the asset and to all it might help 👍

$NGEN I'm man enough to admit to being jealous of people that can add bigly at this price level...

$NGEN nothing will convince me that over 3 fold connectivity increase is just a fun fact and no further investigation is needed. I might be wrong on stock, timing, management but not scientific breakthrough. Given the patent cliff coming in big biotech world it’s an interesting peptyde to look closer to if everything else goes wrong.

Well, $NGEN is doing a great job destroying my portfolio. But I’m still here. If nobody is willing to invest in risky research, how are we ever going to find new treatments? I’d love to make money, but I’d love even more to see people with spinal cord injuries get their lives back. Hopefully we get both.

$NGEN Did you know one of the patients from GRASSP showed improvement by 11 points at Week 12? Three of ten treated participants experienced gains approximately four to five-and-a-half times the cited threshold for a minimally important improvement. And five of ten achieved at least a four-point improvement.